


Applicants: Andrzej Lipkowski et al.  
Serial No.: 10/524,343(a §371 of PCT PCT/PL2003/000077)  
Filed : August 7, 2003  
Page : 3

**In the Claims**

Please replace all previous listing of the claims pursuant with following listing of claims to 37 C.F.R. §1.121:

1. (Currently Amended) A compound ~~with a~~ having the formula ~~represented in Fig. 2:~~



wherein R1 means an amino acid residue is of D-alanine, D-serine, D-threonine, D-methionine, D-leucine, D-asparagine or D-glutamine, and ~~whereas~~ wherein R2 ~~means an amino acid residue of~~ is phenylalanine or tryptophan.

2. (Original) A compound according to claim 1, which is:

(Tyr-D-Ala-Gly-Phe-NH-)<sub>2</sub>

(Tyr-D-Ser-Gly-Phe-NH-)<sub>2</sub>

(Tyr-D-Thr-Gly-Phe-NH-)<sub>2</sub>

(Tyr-D-Met-Gly-Phe-NH-)<sub>2</sub>

Applicants: Andrzej Lipkowski et al.  
Serial No.: 10/524,343(a \$371 of PCT PCT/PL2003/000077)  
Filed : August 7, 2003  
Page : 4

(Tyr-D-Asn-Gly-Phe-NH-)<sub>2</sub>  
(Tyr-D-Leu-Gly-Phe-NH-)<sub>2</sub>  
(Tyr-D-Gln-Gly-Phe-NH-)<sub>2</sub>  
(Tyr-D-Ala-Gly-Trp-NH-)<sub>2</sub>  
(Tyr-D-Ser-Gly-Trp-NH-)<sub>2</sub>  
(Tyr-D-Thr-Gly-Trp-NH-)<sub>2</sub>  
(Tyr-D-Met-Gly-Trp-NH-)<sub>2</sub>  
(Tyr-D-Leu-Gly-Trp-NH-)<sub>2</sub>  
(Tyr-D-Gln-Gly-Trp-NH-)<sub>2</sub> or  
(Tyr-D-Asn-Gly-Phe-NH-)<sub>2</sub>.

3. (Currently Amended) An analgesic medication containing ~~an active ingredient and possibly the compound of claim 1 and a pharmacologically acceptable carrier. and/or excipient, characterised in that as the active ingredient it contains a compound with a formula presented in Fig. 2, where R1 means an amino acid residue of D-alanine, D-serine, D-threonine, D-methionine, D-leucine, D-asparagine or D-glutamine, whereas R2 means an amino acid residue of phenylalanine or tryptophan.~~

4. (Currently Amended) ~~An~~ The analgesic medication according to claim 3, ~~characterised in that the active ingredient wherein the compound is a peptide selected from among:~~

(Tyr-D-Ala-Gly-Phe-NH-)<sub>2</sub>  
(Tyr-D-Ser-Gly-Phe-NH-)<sub>2</sub>  
(Tyr-D-Thr-Gly-Phe-NH-)<sub>2</sub>  
(Tyr-D-Met-Gly-Phe-NH-)<sub>2</sub>

Applicants: Andrzej Lipkowski et al.  
Serial No.: 10/524,343(a \$371 of PCT PCT/PL2003/000077)  
Filed : August 7, 2003  
Page : 5

(Tyr-D-Asn-Gly-Phe-NH-)<sub>2</sub>  
(Tyr-D-Leu-Gly-Phe-NH-)<sub>2</sub>  
(Tyr-D-Gln-Gly-Phe-NH-)<sub>2</sub>  
(Tyr-D-Ala-Gly-Trp-NH-)<sub>2</sub>  
(Tyr-D-Ser-Gly-Trp-NH-)<sub>2</sub>  
(Tyr-D-Thr-Gly-Trp-NH-)<sub>2</sub>  
(Tyr-D-Met-Gly-Trp-NH-)<sub>2</sub>  
(Tyr-D-Leu-Gly-Trp-NH-)<sub>2</sub>  
(Tyr-D-Gln-Gly-Trp-NH-)<sub>2</sub> or  
(Tyr-D-Asn-Gly-Phe-NH-)<sub>2</sub>.

5. (Currently Amended) ~~An~~ The analgesic medication according to claim 3, ~~characterised in that it additionally contains another active ingredient, particularly further comprising a~~ compound selected from ~~among~~ a group consisting of compounds blocking stimulatory amino acid receptors, compounds blocking tachykinin receptors, ~~as well as~~ and compounds blocking cholecystokinin receptors.

6. (Currently Amended) ~~An~~ The analgesic medication according to claim 3, ~~characterised in that it is in the shape of a solution in~~ in the form of an aqueous physiological saline solution.

7. (Currently Amended) ~~An~~ The analgesic medication according to claim 3, characterised in that it is designed for direct

Applicants: Andrzej Lipkowski et al.  
Serial No.: 10/524,343(a \$371 of PCT PCT/PL2003/000077)  
Filed : August 7, 2003  
Page : 6

application to the site of the desired analgesic activity,  
~~particularly by way of constant release or periodic infusion.~~

8. (Currently Amended) ~~An~~ The analgesic medication according to claim 7, characterised in that it is designed for direct application to an appropriate site of the central nervous system.

9. (Currently Amended) ~~An~~ The analgesic medication according to claim 8, ~~characterised in that it contains~~ further comprising biphalline ~~as the active ingredient.~~

~~9. Use of the compound according to claim 1 or 2 for the production of an analgesic medication.~~

~~10. Use according to claim 9, characterised in that in order to produce the medication one additionally uses a compound selected from among compounds blocking stimulatory amino acid receptors, compounds blocking tachykinin receptors, as well as compounds blocking cholecystokinin receptors.~~

11. (Currently Amended) A method of alleviating pain in a subject, comprising administering to the subject at the site of the pain, ~~characterised in that a patient requiring this is given an analgesic medication containing a compound according to claim 1 or 2, where preferentially it is applied directly to the site of the desired analgesic activity.~~

Applicants: Andrzej Lipkowski et al.  
Serial No.: 10/524,343(a \$371 of PCT PCT/PL2003/000077)  
Filed : August 7, 2003  
Page : 7

12. (Currently Amended) A The method according to claim 11, ~~characterised in that the analgesic agent wherein the compound~~ is administered directly to the appropriate site of the central nervous system.

13. (Currently Amended) A The method according to claim 11, ~~characterised in that the analgesic agent contains further~~ comprising administering biphalline.

14. (Currently Amended) A The method according to claim 11, ~~characterised in that analgesic agent additionally contains~~ further comprising administering a compound selected from the group consisting of among compounds blocking stimulatory amino acid receptors, compounds blocking tachykinin receptors, ~~as well as~~ and compounds blocking cholecystokinin receptors.

15. (Currently Amended) A The method according to claim 11, ~~characterised in that the analgesic agent wherein the compound~~ is administered constantly or periodically.

16. (Currently Amended) A The method according to claim 11, ~~characterised in that the analgesic agent is in the shape~~ wherein the compound is in the form of a solution and ~~that~~ it is administered by local infusion.